Advanced/metastatic bladder cancer: current status and future directions.

Area of Science:

• Oncology
• Urology

Background:

• Bladder cancer (BC) is a significant global health issue, ranking as the fourth most frequent malignancy and eighth leading cause of cancer death in 2015.
• Approximately 30% of BC patients are diagnosed with muscle-invasive bladder cancer (MIBC), and 5% present with metastatic bladder carcinoma (MBC).

Purpose of the Study:

• To provide an updated review on the management of metastatic bladder carcinoma (MBC).
• To focus on emerging targeted therapies and immune checkpoint inhibition in MBC treatment.
• To identify prognostic and predictive factors for optimizing patient outcomes.

Main Methods:

• Literature review of current research and clinical guidelines for MBC management.
• Analysis of data regarding first-line combination chemotherapy (CC) regimens, including MVAC and cisplatin-gemcitabine (CG).
• Exploration of novel therapeutic approaches, including targeted therapies and immune checkpoint inhibitors.

Main Results:

• Combination chemotherapy (CC) with MVAC or CG is the standard first-line treatment for fit MBC patients.
• Current CC regimens yield a median progression-free survival (PFS) of 7 months and a median overall survival (OS) of 15 months.
• Emerging targeted therapies and immune checkpoint inhibitors show promise for improving MBC outcomes.

Conclusions:

• The management of MBC is evolving beyond traditional chemotherapy.
• Targeted therapies and immune checkpoint inhibitors represent promising avenues for improving survival and quality of life in MBC patients.
• Further research into prognostic and predictive factors is crucial for personalized MBC treatment strategies.